Hoffmann-La Roche Inc.

Amgen Research (Munich) Gmbh

Takeda Gmbh

Bristol-Myers Squibb Compnay

Engmab Ag

F. Hoffmann-La Roche Ag

Engmab Sarl

Amgen Research Gmbh

Engmab Beta Holdings LLC

Michael Molhoj

Joerg Thomas Regula

Christian Klein

Wolfgang Schaefer

Sabine Imhof-Jung

Ekkehard Moessner

Ulrich Goepfert

Joerg Moelleken

Guy Georges

Hubert Kettenberger

Pablo Umana

Stefan Seeber

Stefan Klostermann

Laurent Lariviere

Tilman Schlothauer

Stefan Dengl

Marina Bacac

Oliver Ast

Olaf Mundigl

Petra Rueger

Harald Duerr

Sebastian Fenn

Jens Niewoehner

Anton Jochner

Kevin Brady

Adrian Hugenmatter

Christian Gassner

Ralf Hosse

Pablo Umaña

Peter Bruenker

Thomas Emrich

Fiona Grueninger

Christiane Neumann

Tanja Fauti

Anne Freimoser-Grundschober

Claudia Ferrara Koller

Guido Hartmann

Alexander Haas

Klaus Strein

Samuel Moser

Peter Michael Huelsmann

Minh Diem Vu

Barbara Weiser

Wolfram Steinhilber

Thomas Urbig

Thomas Boehm

Ramona Murr

Sabine Jung-Imhof

Ralf Schumacher

Christian Schantz

Roland Beckmann

Lydia Jasmin Hanisch

Maximiliane Koenig

Sylvia Herter

Manuel Endesfelder

Sabine Gruener

Sebastian Breuer

Joerg-Thomas Regula

Christiane Jaeger

Marc Bedoucha

Bianca Gruenwalder

Christoph Ullmer

Kristian Hobolt-Jensen

Janina Speck

Katja Montan

Vincent Larraillet

Anne Freimoser-grundschober

Sabine Imhof-jung

Thomas Joerg Regula

Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/anti-human transferrin receptor antibodies

The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

Humanized anti-Tau(PS422) antibodies and methods of use

Herein is reported a method for determining the binding affinity of the binding sites of a bivalent full length antibody of the human IgG1 subclass to a homo-multimeric antigen comprising the steps of i) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain ofat a pH of from pH 7.5 to pH 8.5, in the presence of a reducing agent, at a temperature of from 30° C. to 42° C., for time of from 10 min. to 240 min. to cleave the antibody into Fabs and Fc-region, and ii) determining the binding affinity of the Fabs of the antibody for its antigen using a surface plasmon resonance method by directly applying the incubated reaction mixture obtained in the previous step in the surface plasmon resonance method and therewith determining the binding affinity of the binding sites of the bivalent full length antibody of the human IgG1 subclass.

Direct affinity measurement of human IgG1 binding multimeric antigens

Herein is reported an antibody that specifically hinds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.

Humanized anti-human CD19 antibodies and methods of use

Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use

Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain ofunder conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.

Method for determining the in vivo interaction mode

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.

Bispecific antibodies against CD3EPSILON and ROR1

Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use

The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.

Antibody that binds to VEGF-A and ANG2 and methods of use

Humanized anti-Tau(pS422) antibodies and methods of use

Use of a limited digestion with a proteolytic enzyme of a multispecific antibody for the analysis of the multispecific antibody's light chain pairing.

Method for detecting multispecific antibody light chain mispairing

Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Bispecific T cell activating antigen binding molecules

Growing community of inventors

Munich, Germany

Michael Molhoj